AttendMe Owl Logo
AttendMe
Evidence Evolution
Upper GI SurgeryUpper GI Surgery

How This Evidence Evolved

Gastric Cancer Lymphadenectomy

Defining the Optimal Extent of Lymph Node Dissection for Gastric Cancer

32.3

Timeline

Dutch D1D2 Trial
1995
Dutch D1D2 15-Year
2010
KLASS-02
2019
KLASS-02 (3-year RFS)
2020
JCOG0501
2021
Japanese Gastric Cancer Treatment Guidelines 2025 (7th edition), Japanese Gastric Cancer Association
2025
Japanese Gastric Cancer Association, 2025 guidelines (7th edition; published 2026)
2026
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

The Dutch trial randomized 1078 patients to limited D1 or extended D2 lymphadenectomy; 711 were treated with curative intent. In the early report, D2 had higher operative mortality (10% versus 4%; P=0.004) and complications (43% versus 25%; P<0.001). These results raised concern about the perioperative burden of extended dissection.
Proof

Landmark RCTs and pivotal trials that established the evidence base

At 15 years, the Dutch trial associated D2 with less locoregional recurrence and fewer gastric-cancer-related deaths than D1, despite greater early morbidity. Overall survival was 29% versus 21% (P=0.34), while gastric-cancer-related death was 37% versus 48%. The authors supported D2 where a safer, spleen-preserving technique was available in high-volume centres. These findings distinguish cancer-specific outcomes from overall survival and do not establish a specific learning-curve explanation for the original harm.
Extension

Follow-up studies, subgroup analyses, and real-world validation

KLASS-02, a Korean multicenter RCT of 1,050 patients with locally advanced gastric cancer, compared laparoscopic with open distal gastrectomy with D2 lymphadenectomy. Laparoscopy had lower early morbidity (16.6% vs 24.1%, P=0.003) and shorter hospital stay (8.1 vs 9.3 days), with similar node yield and 90-day mortality (0.4% vs 0.6%). In the long-term report, 3-year relapse-free survival was 80.3% vs 81.3% (HR 1.035, 95% CI 0.762-1.406; P for noninferiority=.039), and the authors called laparoscopic D2 a potential standard option. JCOG0501 (2021) tested neoadjuvant S-1/cisplatin before D2 gastrectomy for type 4 or large type 3 gastric cancer: 3-year overall survival was 60.9% vs 62.4% with surgery first (HR 0.916, 95% CI 0.679-1.236), so D2 surgery followed by adjuvant chemotherapy remains the standard.
Guidelines

Integration into clinical practice guidelines and recommendations

Japanese guidance indicates D2 for curable cT2–T4 or cT1N+ gastric cancer; spleen preservation is advised in proximal advanced disease without greater-curvature involvement. Laparoscopic gastrectomy requires a qualified surgeon or equivalent supervision.
Japanese Gastric Cancer Association, 2025 guidelines (7th edition; published 2026)

D2 for potentially curable cT2–T4 or cT1N+; laparoscopic distal gastrectomy ≥Stage II strongly recommended with qualified supervision.

Now

Current standard of care and ongoing research directions

Japanese guidance recommends D2 for potentially curable cT2–T4 or cT1N+ disease. Extent of organ resection must reflect invasion: spleen preservation is advised in proximal advanced tumours without greater-curvature involvement, while adjacent-organ invasion can require combined resection. KLASS-02 supports laparoscopic distal gastrectomy with D2 in locally advanced gastric cancer. The guideline requires laparoscopic skill qualification or equivalent supervision; this is more specific than treating every D2 procedure as universally interchangeable.

Landmark Trials in This Story

Dutch D1D2 Trial1995Landmark

Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients

Operative mortality: D2 10% vs D1 4% (P=0.004); complications: 43% vs 25% (P<0.001)

LancetRCTN=1,078
Dutch D1D2 15-Year2010Landmark

Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial

15-year gastric cancer-related death — D2 lower locoregional recurrence and cancer-specific death vs D1

Lancet OncolRCTN=1,078
KLASS-022019Landmark

Short-term Outcomes of a Multicenter Randomized Controlled Trial Comparing Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy to Open Distal Gastrectomy for Locally Advanced Gastric Cancer (KLASS-02-RCT)

30-day morbidity: laparoscopic 16.6% vs open 24.1% (P=0.003); 90-day mortality 0.4% vs 0.6% (P=0.682)

Ann SurgRCTN=1,050
JCOG05012021

Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial

Overall survival — neoadjuvant S-1/cisplatin did not improve survival vs D2 gastrectomy with adjuvant therapy

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationRCTN=316
KLASS-02 (3-year RFS)2020

Long-Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS-02-RCT Randomized Clinical Trial.

3-year relapse-free survival: laparoscopic 80.3% vs open 81.3% (HR 1.035, 95% CI 0.762-1.406; P for noninferiority=.039)

J Clin OncolRandomized noninferiority trial; hazard-ratio upper margin 1.43N=1,050

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

Why did the view on D2 lymphadenectomy change over time?+
The early Dutch report found higher mortality (10% versus 4%) and complications (43% versus 25%) after D2. At 15 years, D2 had less locoregional recurrence and fewer gastric-cancer-related deaths; overall survival did not differ significantly. The authors supported a safer spleen-preserving D2 technique in high-volume centres. The reports do not establish the claimed learning-curve cause or Asian 2–3% mortality rate.
Can D2 lymphadenectomy be done laparoscopically?+
KLASS-02 (1,050 patients) found laparoscopic distal gastrectomy with D2 noninferior to open surgery for locally advanced gastric cancer: 3-year relapse-free survival 80.3% vs 81.3% (P for noninferiority=.039), with fewer early complications (15.7% vs 23.4%). The 2025 Japanese guidelines strongly recommend laparoscopic distal gastrectomy for Stage II or more, by or under the guidance of a qualified surgeon.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026